Cardiff Oncology Inc. (NASDAQ:CRDF) finished Thursday with a subtraction of $0.0 to close at $2.07, a downside of 0.00 percent. An average of 5,133,514 shares of common stock have been traded in the last five days. There was a gain of $0.46 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,416,553 shares traded, while the 50-day average volume stands at 651,291.
CRDF stock has increased by 43.75% in the last month. The company shares reached their 1-month lowest point of $1.38 on 07/13/23. With the stock rallying to its 52-week high on 08/08/23, shares of the company touched a low of $1.20 and a high of $3.31 in 52 weeks. It has reached a new high 9 times so far this year and achieved 47.86% or $0.77 in price. In spite of this, the price is down -37.46% from the 52-week high.
Valuation Metrics
Cardiff Oncology Inc. (CRDF) stock’s beta is 1.66. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 228.48, the price-to-book (PB) ratio at 0.96.
Financial Health
The quick ratio of Cardiff Oncology Inc. for the three months ended June 29 was 12.50, and the current ratio was 12.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Cardiff Oncology Inc.’s EBITDA margin for the year ending June 29 is -10285.49%. Its gross profit as reported stood at $0.39 million compared to revenue of $0.39 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cardiff Oncology Inc.’s return on assets was -32.60%.
Earnings Surprise
For the three-month period that ended June 29, Cardiff Oncology Inc. had $70.06 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$11.16 million in the quarter, while revenues of -$11.23 million were grew 15.32%. The analyst consensus anticipated Cardiff Oncology Inc.’s latest quarter earnings to come in at -$0.26 per share, but it turned out to be -$0.25, a 3.80% surprise. For the quarter, EBITDA amounted to -$12.35 million. Shareholders own equity worth $44.68 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Cardiff Oncology Inc. (CRDF) price momentum. RSI 9-day as of the close on 10 August was 67.28%, suggesting the stock is Neutral, with historical volatility in this time frame at 200.67%.
As of today, CRDF’s price is $1.98 +26.90% or $0.46 from its 5-day moving average. CRDF is currently trading +53.90% higher than its 20-day SMA and +25.43% higher than its 100-day SMA. However, the stock’s current price level is +34.78% above the SMA50 and +53.90% above the SMA200.
The stochastic %K and %D were 46.38% and 44.85%, respectively, and the average true range (ATR) was 0.27. With the 14-day stochastic at 55.07% and the average true range at 0.22, the RSI (14) stands at 65.69%. The stock has reached 0.18 on the 9-day MACD Oscillator while the 14-day reading was at 0.30.
Analyst Ratings
William Blair launched coverage on Cardiff Oncology Inc. (NASDAQ: CRDF) in its analyst report released on January 05, 2022. The firm assigned the stock an Outperform rating. The consensus rating for Cardiff Oncology Inc. (CRDF) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CRDF, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 4 others rate it as a “buy”.
What is CRDF’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $12.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Cardiff Oncology Inc. (CRDF) stock is $7.33.
